Today: 4 June 2026

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Linde (LIN) Stock After Hours on December 9, 2025: 52‑Week Lows, CEO Buying, and What to Watch Before the December 10 Open

Linde (LIN) Stock After Hours on December 9, 2025: 52‑Week Lows, CEO Buying, and What to Watch Before the December 10 Open

Linde shares closed at $390.38 on December 9, up 0.26% after a sharp sell-off, but slipped to $389.35 in after-hours trading. The stock is near its 52-week low of $387.78 and trades about 7% below its 2025 starting price, despite strong earnings. CEO recently bought nearly $1 million in shares. Wall Street projects about 30% upside over the next year.
10 December 2025
·
Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025

Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025

Ascendis Pharma shares fell 4.2% to around $197.25 in late trading December 9 after a Q3 earnings miss and a three-month FDA review delay for its key dwarfism drug. Volume was about 76% below average. The company posted Q3 revenue of €213.6 million but reported a net loss of €61 million, mainly from finance expenses. Despite the pullback, ASND remains near its 52-week high and up year-on-year.
9 December 2025
··
KE Holdings (BEKE) Stock Slides as Buybacks Accelerate: What Q3 2025 Earnings and China’s Housing Slump Mean for Investors

KE Holdings (BEKE) Stock Slides as Buybacks Accelerate: What Q3 2025 Earnings and China’s Housing Slump Mean for Investors

KE Holdings (NYSE: BEKE) shares fell about 4.8% Tuesday, opening near $16.35 after closing at $17.08, with over 1 million shares traded. The drop came despite ongoing share buybacks and Q3 revenue rising 2.1% year-on-year to RMB 23.1 billion. Net income fell to RMB 747 million from RMB 1.17 billion a year earlier. BEKE underperformed even as international ETF VXUS saw strong inflows.
9 December 2025
····
O’Reilly Automotive (ORLY) Stock Outlook: Institutional Buying, Q3 Beat and 2026 Growth Drivers as of December 9, 2025

O’Reilly Automotive (ORLY) Stock Outlook: Institutional Buying, Q3 Beat and 2026 Growth Drivers as of December 9, 2025

O’Reilly Automotive shares fell 3.9% to $94.31 on December 9, 2025, with trading volume near 5 million, following a recent stock split. Multiple large institutional investors disclosed sharply increased stakes. Third-quarter results showed 5.6% same-store sales growth and a 12% rise in diluted EPS to $0.85, beating estimates. Management raised the lower end of 2025 revenue guidance.
9 December 2025
Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics shares traded at $17–18 on December 9, 2025, near the low end of their 52-week range of $15.55 to $36.91. The company’s lung cancer drug ivonescimab recently outperformed Keytruda in a limited trial, drawing attention but also regulatory questions. Summit granted inducement stock options to new hires on December 5. The company’s market cap stands near $13–14 billion.
9 December 2025
·
Credo Technology Group (CRDO) Stock: Earnings Blowout, AI Tailwinds, and What Comes Next

Credo Technology Group (CRDO) Stock: Earnings Blowout, AI Tailwinds, and What Comes Next

Credo Technology Group shares traded near $169 on December 9, 2025, down from a record $213.80 hit a week earlier after strong earnings. The company reported Q2 fiscal 2026 revenue of $268 million, far above estimates, and net income of $82.6 million versus a loss last year. Management raised Q3 guidance to $335–$345 million in revenue, citing demand from AI data centers.
9 December 2025
···
Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals shares traded at $26–27 on December 9, up over 800% from their 52-week low but 12% below the recent high. The stock surged after Roche’s positive Phase 3 results for a similar breast cancer drug, triggering analyst upgrades and price target hikes. Market capitalization now stands near $2–2.2 billion. Analyst 12-month targets range from $20 to $55, with most rating the stock a strong buy.
9 December 2025
··
Ferguson Enterprises (FERG) Stock Slides After Q1 2026 Earnings – What Today’s Sell-Off Means for Investors

Ferguson Enterprises (FERG) Stock Slides After Q1 2026 Earnings – What Today’s Sell-Off Means for Investors

Ferguson Enterprises reported Q1 net sales of $8.17–8.2 billion, up 5.1% year-on-year, and adjusted diluted EPS of $2.84, up 15.9%. Shares fell sharply despite raised full-year guidance, as investors weighed valuations and growth forecasts. Residential revenue slipped 1%, while non-residential revenue jumped 12% on strong commercial demand. The company now targets 5% net sales growth for 2025.
9 December 2025
···
Graphic Packaging (GPK) Stock Hits 52-Week Low as Earnings Guidance Cut and CEO Transition Rattle Investors

Graphic Packaging (GPK) Stock Hits 52-Week Low as Earnings Guidance Cut and CEO Transition Rattle Investors

Graphic Packaging shares fell to a new 52-week low near $14 on December 9, 2025, after the company cut its full-year earnings outlook and announced cost and production optimization measures. Trading volume topped 10 million shares. The company also confirmed a CEO transition for early 2026. Net sales guidance remains at $8.4–$8.6 billion.
9 December 2025
··
SLM Stock Plunges Over 16% After Investor Day: New EPS Targets, Analyst Downgrades and 2026–2028 Outlook for Sallie Mae (SLM)

SLM Stock Plunges Over 16% After Investor Day: New EPS Targets, Analyst Downgrades and 2026–2028 Outlook for Sallie Mae (SLM)

SLM Corporation shares plunged 16–17% to about $25.85 on December 9 after its Investor Forum revealed sharply lower earnings guidance for 2026 and 2027. Management projected FY26 EPS of $2.63, about 23% below prior consensus, and signaled higher operating expenses tied to a strategic shift. Trading volume was several times normal. The stock now trades just above its 52-week low.
9 December 2025
·
Inspire Medical Systems (INSP) Stock on December 9, 2025: Rebound Rally Meets Legal Overhang and Mixed Analyst Targets

Inspire Medical Systems (INSP) Stock on December 9, 2025: Rebound Rally Meets Legal Overhang and Mixed Analyst Targets

Inspire Medical Systems shares traded at $141.72 on December 9, 2025, after a volatile year that included a 21% surge two weeks prior following an analyst upgrade and positive reimbursement news. Q3 revenue rose 10% to $224.5 million, with net income at $9.9 million and adjusted EPS of $0.38, beating estimates. The company also launched its new Inspire 5 system.
9 December 2025
·
Kontoor Brands (KTB) Stock on December 9, 2025: Q3 Beat, Analyst Upgrades and Volatile Trading Create a 2026 Upside Story

Kontoor Brands (KTB) Stock on December 9, 2025: Q3 Beat, Analyst Upgrades and Volatile Trading Create a 2026 Upside Story

Kontoor Brands shares traded between $75 and $76 on December 9, about 19% below their January high, after falling 3–4% intraday amid weak consumer data. Wells Fargo raised its price target to $100 and reiterated an “overweight” rating. Marshall Wace trimmed its stake following recent gains. Kontoor’s Q3 revenue rose 27% to $853 million, with EPS of $1.44 beating forecasts.
9 December 2025
··
AutoZone (AZO) Stock Plunges After Q1 2026 Earnings Miss — What Investors Need to Know Today

AutoZone (AZO) Stock Plunges After Q1 2026 Earnings Miss — What Investors Need to Know Today

AutoZone shares fell about 7–8% Tuesday after fiscal Q1 2026 results missed profit estimates, making it the S&P 500’s worst performer. Net sales rose 8.2% to $4.63 billion, but net income dropped to $530.8 million from $564.9 million a year earlier. Diluted EPS came in at $31.04, below analyst forecasts and marking a sixth straight quarterly miss. Trading volume surged as investors reacted to weaker margins and guidance.
9 December 2025
··
D-Wave Quantum (QBTS) Stock in December 2025: Rally, Volatility, and What Analysts Expect Next

D-Wave Quantum (QBTS) Stock in December 2025: Rally, Volatility, and What Analysts Expect Next

D-Wave Quantum shares traded at $27–28 on December 9, 2025, up over 200% year to date after sharp swings. The stock plunged nearly 40% in November before rebounding more than 20% in early December, driven by bullish analyst coverage and renewed investor interest. Evercore ISI initiated coverage with an “Outperform” rating and a $44 target. Institutional investors have increased positions as volatility remains high.
9 December 2025
···
Hawaiian Electric Industries (HE) Stock Soars on S&P 600 Inclusion – Latest News, Maui Settlement Update and 2026 Forecasts

Hawaiian Electric Industries (HE) Stock Soars on S&P 600 Inclusion – Latest News, Maui Settlement Update and 2026 Forecasts

Hawaiian Electric Industries stock surged over 11% on December 8, 2025, after S&P Dow Jones Indices announced its addition to the S&P SmallCap 600. Shares traded near $11.73 on December 9, with market cap at $2.1 billion. The move follows a year of legal pressure from Maui wildfire settlements, with analysts maintaining a “Hold” rating. Trading volume spiked to 1.4 million shares, well above normal levels.
9 December 2025
··
1 … 499 500 501 502 503 … 587

Stock Market Today

  • Howmet Aerospace's Defense Market Momentum Drives Revenue Growth
    June 4, 2026, 2:48 PM EDT. Howmet Aerospace Inc. (HWM) saw a 10% year-over-year revenue rise in Q1 2026, driven by strong demand in its defense aerospace sector, notably from the F-35 engine spares and legacy fighter jet parts. The Engine Products segment led with a 29% revenue increase. The 2026 Defense Appropriations Act bolsters this momentum through increased defense budgets. Peers like Honeywell and GE Aerospace also reported gains, with GE securing a $1.4 billion engine deal. HWM's shares surged 21.3% year-to-date, outperforming the industry. Despite trading at a high forward price-to-earnings ratio of 46.31X, earnings estimates for 2026 have risen by 9%. HWM holds a Zacks Rank #2 (Buy), supported by strong defense spending and geopolitical factors.

Latest articles

Palantir Stock Dips Despite Google AI News

Palantir Stock Dips Despite Google AI News

4 June 2026
Palantir shares fell 0.9% to $140.89 despite announcing a deeper Google Cloud partnership and new commercial deals at its AIPCon event, as investors weigh whether these moves will drive durable revenue growth amid ongoing valuation sensitivity, government-contract scrutiny, and shareholder pressure.
Grab Stock Bounces While Nasdaq Sags—What Traders Are Waiting For Next

Grab Stock Bounces While Nasdaq Sags—What Traders Are Waiting For Next

4 June 2026
Grab Holdings’ U.S. shares jumped 2.9% to $3.51 as investors weighed strong Q1 results—revenue up 24% to $955 million, adjusted EBITDA up 46% to $154 million—and the consolidation of Indonesia’s Superbank, now majority-owned by Grab, against risks from higher fuel costs and regional regulation, leaving the stock sensitive to further updates on profitability and fintech growth.
Goldman Sachs Jumps as Dow Sets New High

Goldman Sachs Jumps as Dow Sets New High

4 June 2026
Goldman Sachs shares surged 4.6% to $1,095.89, powering the Dow to an all-time high as investors rotated into financials; the move was amplified by Goldman’s high share price in the price-weighted Dow, while the bank’s lead role in the $75 billion SpaceX IPO and strong Q1 earnings added momentum, even as analysts flagged risks from high IPO valuations and geopolitical uncertainty.
Celsius Drops in New York After Texas Inquiry Hits Alani Nu Play

Celsius Drops in New York After Texas Inquiry Hits Alani Nu Play

4 June 2026
Celsius shares plunged 6.8% to near a 52-week low after Texas opened a probe into whether its Alani Nu drinks misled consumers about safety for minors, raising fresh legal and consumer-safety concerns just as the company relies on Alani Nu for growth and integration with PepsiCo’s distribution system.
Veru shares jump after Novo Nordisk deal draws traders

Veru shares jump after Novo Nordisk deal draws traders

4 June 2026
Veru shares soared 112% to $4.78 after announcing Novo Nordisk will supply Wegovy at no charge for Veru’s Phase 2b obesity trial, with Veru retaining global rights to enobosarm but granting Novo a right of first negotiation; analysts called the deal a “significant event” and kept $24–$25 targets, while Veru warned trial risks and reimbursement challenges remain.
Go toTop